{
    "clinical_study": {
        "@rank": "125949", 
        "acronym": "BASIS", 
        "arm_group": [
            {
                "arm_group_label": "Peginterferon Lambda-1a + Ribavirin", 
                "arm_group_type": "Experimental", 
                "description": "Peginterferon Lambda-1a 180 \u03bcg solution for subcutaneous (sc) injection once weekly and Ribavirin 1000 or 1200 mg based on weight tablet by mouth twice daily for 48 weeks"
            }, 
            {
                "arm_group_label": "Peginterferon alfa-2a + Ribavirin", 
                "arm_group_type": "Active Comparator", 
                "description": "Peginterferon alfa-2a 180 \u03bcg solution for subcutaneous (sc) injection once weekly and Ribavirin 1000 or 1200 mg based on weight tablet by mouth twice daily for 48 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if 48 weeks of therapy with Peginterferon Lambda\n      plus Ribavirin is effective and safe for a treatment of chronic hepatitis C (CHC) compared\n      to therapy with Peginterferon alfa-2a plus Ribavirin."
        }, 
        "brief_title": "Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C Virus (HCV)", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chronic hepatitis C, Genotype 1\n\n          -  HCV RNA \u2265100,000 IU/mL at screening\n\n          -  Liver biopsy documenting no cirrhosis (within prior 3 years). Where approved for\n             staging of liver disease, non-invasive imaging may be used to assess the extent of\n             liver disease\n\n          -  Na\u00efve to prior anti-HCV therapy\n\n        Exclusion Criteria:\n\n          -  Infected with HCV other than Genotype 1\n\n          -  Positive Hepatitis B Surface Antigen (HBsAg), or Human Immunodeficiency Virus\n             (HIV)-1/HIV-2 antibody at screening\n\n          -  Evidence of liver disease other than HCV\n\n          -  Active substance abuse\n\n          -  Use of hematologic growth factors within 90 days prior to study randomization\n\n          -  Evidence of history of cirrhosis based on radiologic criteria or biopsy results and\n             clinical criteria"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01754974", 
            "org_study_id": "AI452-033", 
            "secondary_id": "2012-003508-11"
        }, 
        "intervention": [
            {
                "arm_group_label": "Peginterferon Lambda-1a + Ribavirin", 
                "intervention_name": "Peginterferon Lambda-1a", 
                "intervention_type": "Biological", 
                "other_name": "BMS-914143"
            }, 
            {
                "arm_group_label": [
                    "Peginterferon Lambda-1a + Ribavirin", 
                    "Peginterferon alfa-2a + Ribavirin"
                ], 
                "intervention_name": "Ribavirin", 
                "intervention_type": "Drug", 
                "other_name": "Ribasphere"
            }, 
            {
                "arm_group_label": "Peginterferon alfa-2a + Ribavirin", 
                "intervention_name": "Peginterferon alfa-2a", 
                "intervention_type": "Biological", 
                "other_name": "Pegasys"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ribavirin", 
                "Peginterferon alfa-2a", 
                "Interferon-alpha"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 27, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trial Information", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "BMS clinical trial educational resource", 
                "url": "http://www.bms.com/studyconnect/Pages/home.aspx"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hradec Kralove", 
                        "country": "Czech Republic", 
                        "zip": "500 05"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha 4", 
                        "country": "Czech Republic", 
                        "zip": "140 00"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Usti Nad Labem", 
                        "country": "Czech Republic", 
                        "zip": "400 01"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chungcheongnam-do", 
                        "country": "Korea, Republic of", 
                        "zip": "330-930"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of", 
                        "zip": "700-821"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gangwon-do", 
                        "country": "Korea, Republic of", 
                        "zip": "200-704"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gyeonggi-do", 
                        "country": "Korea, Republic of", 
                        "zip": "463-707"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gyeonggi-do", 
                        "country": "Korea, Republic of", 
                        "zip": "420-717"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gyeongsangnam-do", 
                        "country": "Korea, Republic of", 
                        "zip": "626-770"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Incheon", 
                        "country": "Korea, Republic of", 
                        "zip": "403-720"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "156-755"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mexico", 
                        "country": "Mexico", 
                        "state": "Distrito Federal", 
                        "zip": "07760"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mexico City", 
                        "country": "Mexico", 
                        "state": "Estado De Mexico", 
                        "zip": "06700"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guadalajara", 
                        "country": "Mexico", 
                        "state": "Jalisco", 
                        "zip": "44500"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guadalajara", 
                        "country": "Mexico", 
                        "state": "Jalisco", 
                        "zip": "44650"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Distrito Federal", 
                        "country": "Mexico", 
                        "zip": "03720"
                    }, 
                    "name": "Local Institution"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Czech Republic", 
                "Korea, Republic of", 
                "Mexico"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-Blinded, Randomized Control Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a, Each in Combination With Ribavirin, in the Treatment of Naive Genotype 1 Chronic Hepatitis C Subjects", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Suspended", 
        "oversight_info": {
            "authority": [
                "Korea: Food and Drug Administration", 
                "Brazil: National Health Surveillance Agency", 
                "Brazil: Ministry of Health", 
                "Brazil: National Committee of Ethics in Research", 
                "Czech Republic: State Institute for Drug Control", 
                "Hungary: National Institute of Pharmacy", 
                "Mexico: Ministry of Health", 
                "Poland: National Institute of Medicines", 
                "Poland: Ministry of Health", 
                "Poland: Ministry of Science and Higher Education", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Romania: National Medicines Agency", 
                "Russia: Ethics Committee", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Russia: FSI Scientific Center of Expertise of Medical Application", 
                "Turkey: Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "ANC = Absolute Neutrophil Count\nHb = Hemoglobin", 
            "measure": "Proportion of subjects who develop treatment emergent cytopenic abnormalities (anemia as defined by Hb < 10 g/dL, and/or neutropenia as defined by ANC < 750 mm3 and/or thrombocytopenia as defined by platelets < 50,000 mm3) in treatment-naive subjects", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 48 weeks of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01754974"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of subjects with Sustained Virologic Response at Post-Treatment Follow-up Week 24 (SVR24), defined as Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) < Lower Limit of Quantitation of Assay (LLOQ)", 
                "safety_issue": "No", 
                "time_frame": "At Post-Treatment Follow-up Week 24"
            }, 
            {
                "measure": "Proportion of subjects with Rapid Virologic Response (RVR) (HCV RNA not detected)", 
                "safety_issue": "No", 
                "time_frame": "On treatment Week 4 (of an up to 48-week treatment period)"
            }, 
            {
                "measure": "Proportion of subjects with on-treatment Serious Adverse Events (SAEs) through end of treatment", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 48 weeks of treatment"
            }, 
            {
                "measure": "Proportion of subjects with dose reductions through end of treatment", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 48 weeks of treatment"
            }, 
            {
                "measure": "Proportion of subjects who discontinue due to Adverse Events (AEs) through end of treatment", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 48 weeks of treatment"
            }, 
            {
                "description": "On-treatment IFN-associated symptoms are:\nFlu-like symptoms (as defined by pyrexia or chills or pain)\nMusculoskeletal symptoms (as defined by arthralgia or myalgia or back pain)\nNeurological symptoms (headache or dizziness)\nConstitutional symptoms (fatigue or asthenia)\nPsychiatric symptoms (depression or irritability or insomnia)", 
                "measure": "Proportion of subjects with on-treatment Interferon (IFN)-associated symptoms as determined by adverse event reporting", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 48 weeks of treatment"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}